$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

$bcli Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-K Financial Statement

#000114420415018682 Filed on March 26, 2015

Income Statement

Concept	2015 Q1	2014	2013 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$960.0K	$2.650M	$550.0K
YoY Change	174.29%	24.41%	57.14%
% of Gross Profit
Research & Development	$1.245M	$4.772M	$850.0K
YoY Change	83.09%	63.59%	203.57%
% of Gross Profit
Depreciation & Amortization	$20.00K	$106.0K	$20.00K
YoY Change	-33.33%	9.28%	-50.0%
% of Gross Profit
Operating Expenses	$2.205M	$7.421M	$1.400M
YoY Change	113.87%	47.15%	122.22%
Operating Profit	-$2.205M	-$7.421M
YoY Change	4.45%	51.48%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$30.00K	-$1.830M	$170.0K
YoY Change	-97.22%	-1407.14%	183.33%
Pretax Income	-$2.240M	-$3.789M	-$1.240M
YoY Change	6.16%	214.44%	113.79%
Income Tax	$0.00	$0.00	-$20.00K
% Of Pretax Income
Net Earnings	-$2.236M	-$9.246M	-$1.220M
YoY Change	5.92%	88.73%	110.34%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$123.6K	-$677.2K	-$97.37K
COMMON SHARES
Basic Shares Outstanding	18.39M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q1	2014	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.35M	$8.540M	$3.500M
YoY Change	604.62%	144.0%	-14.43%
Cash & Equivalents	$3.494M	$4.250M	$3.503M
Short-Term Investments	$17.86M	$4.290M	$0.00
Other Short-Term Assets	$40.00K	$30.00K	$30.00K
YoY Change	33.33%	0.0%	-40.0%
Inventory
Prepaid Expenses	$36.00K		$33.00K
Receivables	$690.0K	$1.010M	$910.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$22.08M	$9.580M	$4.446M
YoY Change	473.01%	115.28%	-8.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$290.0K	$310.0K	$258.0K
YoY Change	-11.31%	19.23%	4.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$20.00K	$20.00K	$20.00K
YoY Change	100.0%	0.0%	0.0%
Total Long-Term Assets	$309.0K	$330.0K	$280.0K
YoY Change	-9.12%	17.86%	6.06%
TOTAL ASSETS
Total Short-Term Assets	$22.08M	$9.580M	$4.446M
Total Long-Term Assets	$309.0K	$330.0K	$280.0K
Total Assets	$22.39M	$9.910M	$4.726M
YoY Change	433.91%	109.51%	-8.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$922.0K	$1.540M	$228.0K
YoY Change	182.82%	569.57%	-36.31%
Accrued Expenses	$1.571M	$1.350M	$877.0K
YoY Change	51.93%	53.41%	44.96%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.726M	$3.110M	$1.332M
YoY Change	69.63%	133.83%	15.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$120.0K	$660.0K
YoY Change	-100.0%	-81.82%
Total Long-Term Liabilities	$0.00	$120.0K	$655.0K
YoY Change	-100.0%	-81.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.726M	$3.110M	$1.332M
Total Long-Term Liabilities	$0.00	$120.0K	$655.0K
Total Liabilities	$2.726M	$3.240M	$1.987M
YoY Change	-18.21%	62.81%	71.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$63.89M		-$52.41M
YoY Change
Common Stock	$83.55M		$55.15M
YoY Change	50.87%		7.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.66M	$6.680M	$2.739M
YoY Change
Total Liabilities & Shareholders Equity	$22.39M	$9.910M	$4.726M
YoY Change	433.91%	109.51%	-8.02%

Cashflow Statement

Concept	2015 Q1	2014	2013 Q4
OPERATING ACTIVITIES
Net Income	-$2.236M	-$9.246M	-$1.220M
YoY Change	5.92%	88.73%	110.34%
Depreciation, Depletion And Amortization	$20.00K	$106.0K	$20.00K
YoY Change	-33.33%	9.28%	-50.0%
Cash From Operating Activities	-$1.937M	-$4.487M	-$1.600M
YoY Change	395.4%	10.68%	128.57%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$161.0K	-$10.00K
YoY Change	-100.0%	49.07%	0.0%
Acquisitions
YoY Change
Other Investing Activities	-$13.57M	-$4.290M	$4.790M
YoY Change	-135800.0%	-255.43%	-274.18%
Cash From Investing Activities	-$13.57M	-$4.450M	$4.790M
YoY Change	15858.82%	-267.55%	-273.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$2.348M	$9.554M
YoY Change		167.17%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$14.75M	$9.685M	0.000
YoY Change		170.23%
NET CHANGE
Cash From Operating Activities	-$1.937M	-$4.487M	-1.600M
Cash From Investing Activities	-$13.57M	-$4.450M	4.790M
Cash From Financing Activities	$14.75M	$9.685M	0.000
Net Change In Cash	-$757.0K	$748.0K	3.190M
YoY Change	59.03%	-65.78%	-192.2%
FREE CASH FLOW
Cash From Operating Activities	-$1.937M	-$4.487M	-$1.600M
Capital Expenditures	$0.00	$161.0K	-$10.00K
Free Cash Flow	-$1.937M	-$4.648M	-$1.590M
YoY Change	299.38%	11.68%	130.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3503000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4251000	USD
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	4290000	USD
CY2013Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	910000	USD
CY2014Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	1005000	USD
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	33000	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	32000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	4446000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	9578000	USD
CY2013Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	22000	USD
CY2014Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	20000	USD
CY2013Q4	us-gaap	Long Term Investments LongTermInvestments	22000	USD
CY2014Q4	us-gaap	Long Term Investments LongTermInvestments	20000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	258000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	313000	USD
CY2013Q4	us-gaap	Assets Assets	4726000	USD
CY2014Q4	us-gaap	Assets Assets	9911000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	228000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1542000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	877000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1347000	USD
CY2013Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	227000	USD
CY2014Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	224000	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	655000	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	123000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1332000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3113000	USD
CY2013Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	655000	USD
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	123000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	1987000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	3236000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	55138000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	68317000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52407000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61653000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	6675000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4726000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9911000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	872000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	1222000	USD
	invest	Investment Warrants Exercise Price InvestmentWarrantsExercisePrice	2.25
CY2009	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	74667	shares
	bcli	Stock Option Expiration Term StockOptionExpirationTerm	P10Y
CY2011Q1	bcli	Amount Due To Investors AmountDueToInvestors	20000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	53333	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11750881	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15281497	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11750881	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15281497	shares
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2917000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4772000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2126000	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2649000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	5043000	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	7421000	USD
CY2013	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	-144000	USD
CY2014	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	1825000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-4899000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-9246000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.46
CY2014	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.68
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10738131	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13662758	shares
CY2013	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	197000	USD
CY2014	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	198000	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	674000	USD
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1024000	USD
CY2013	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	250000	USD
CY2014	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	9554000	USD
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	30000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30000	USD
CY2014	bcli	Stock Issued During Period Value Issued For Warrants Exchange StockIssuedDuringPeriodValueIssuedForWarrantsExchange	1633000	USD
CY2014	bcli	Adjustments To Additional Paid In Capital Warrant Redemption In Cash AdjustmentsToAdditionalPaidInCapitalWarrantRedemptionInCash	42000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-4899000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-9246000	USD
CY2014	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	701000	USD
CY2013	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	97000	USD
CY2014	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	106000	USD
CY2013	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	227000	USD
CY2014	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	198000	USD
CY2013	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	674000	USD
CY2014	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1024000	USD
CY2013	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	155000	USD
CY2014	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	93000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-130000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1314000	USD
CY2013	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	306000	USD
CY2014	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	467000	USD
CY2013	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-174000	USD
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1743000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4054000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4487000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	108000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	161000	USD
CY2013	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-2769000	USD
CY2014	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	4290000	USD
CY2013	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	5000	USD
CY2014	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	-1000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2656000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4450000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3576000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9554000	USD
CY2013	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	8000	USD
CY2014	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	731000	USD
CY2013	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2014	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	600000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3584000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9685000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2186000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	748000	USD
CY2013	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2014	us-gaap	Stock Issued1 StockIssued1	1633000	USD
CY2013	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2014	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	42000	USD
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Entity Registrant Name EntityRegistrantName	BRAINSTORM CELL THERAPEUTICS INC.
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001137883
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q2	dei	Entity Public Float EntityPublicFloat	67525553	USD
CY2014	dei	Trading Symbol TradingSymbol	BCLI
CY2015Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18393546	shares
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 56.7pt"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 28.35pt"> <div style="CLEAR:both;CLEAR: both"><font style="COLOR: black"> B.</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="COLOR: black">Use of estimates:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="COLOR: black; FONT-WEIGHT: normal"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.0833	pure
CY2013Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	60000	USD
CY2014Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	43000	USD
CY2013Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	850000	USD
CY2014Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	962000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1365000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1524000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1107000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1211000	USD
CY2013	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	248000	USD
CY2014	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	164000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-5457000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4899000	USD
CY2013Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	25156000	USD
CY2014Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	29222000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8961000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10994000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8961000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10994000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1205000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-3789000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3694000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-9246000	USD
CY2013	us-gaap	Depreciation Depreciation	97000	USD
CY2014	us-gaap	Depreciation Depreciation	106000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	181000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	103000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	54000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	55000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	57000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	450000	USD
CY2013	bcli	Research And Development Cost ResearchAndDevelopmentCost	4030000	USD
CY2014	bcli	Research And Development Cost ResearchAndDevelopmentCost	6116000	USD
CY2013	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	1113000	USD
CY2014	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	1344000	USD
CY2014	bcli	Grants Underlying Basis GrantsUnderlyingBasis	The grant is linked to the exchange rate of the dollar and bears interest of Libor per annum.
CY2014	bcli	Amounts Of Grants Received AmountsOfGrantsReceived	1169000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	412388	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	792110	shares
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M25D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M6D
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	335795	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	331500	shares
CY2012Q4	bcli	Share Based Goods And Nonemployee Services Transaction Securities Outstanding Number ShareBasedGoodsAndNonemployeeServicesTransactionSecuritiesOutstandingNumber	786387	shares
CY2013Q4	bcli	Share Based Goods And Nonemployee Services Transaction Securities Outstanding Number ShareBasedGoodsAndNonemployeeServicesTransactionSecuritiesOutstandingNumber	840367	shares
CY2013	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	53980	shares
CY2014	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	23419	shares
CY2012Q4	bcli	Share Based Goods And Non Employee Services Transaction Securities Outstanding Weighted Average Issue Price ShareBasedGoodsAndNonEmployeeServicesTransactionSecuritiesOutstandingWeightedAverageIssuePrice	4.05
CY2013Q4	bcli	Share Based Goods And Non Employee Services Transaction Securities Outstanding Weighted Average Issue Price ShareBasedGoodsAndNonEmployeeServicesTransactionSecuritiesOutstandingWeightedAverageIssuePrice	4.02
CY2013	bcli	Share Based Goods And Nonemployee Services Transaction Weighted Average Issue Price Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionWeightedAverageIssuePriceOfSecuritiesIssued	3.60
CY2014	bcli	Share Based Goods And Nonemployee Services Transaction Weighted Average Issue Price Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionWeightedAverageIssuePriceOfSecuritiesIssued	4.91
CY2014Q4	bcli	Share Based Goods And Nonemployee Services Transaction Securities Outstanding Number ShareBasedGoodsAndNonemployeeServicesTransactionSecuritiesOutstandingNumber	863786	shares
CY2014Q4	bcli	Share Based Goods And Non Employee Services Transaction Securities Outstanding Weighted Average Issue Price ShareBasedGoodsAndNonEmployeeServicesTransactionSecuritiesOutstandingWeightedAverageIssuePrice	4.07
CY2013	bcli	Expenses Related To Shares And Options Granted To Service Providers ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders	197000	USD
CY2014	bcli	Expenses Related To Shares And Options Granted To Service Providers ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders	198000	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure

Files In Submission

Name	View Source	Status
0001144204-15-018682-index-headers.html	Edgar Link	pending
0001144204-15-018682-index.html	Edgar Link	pending
0001144204-15-018682.txt	Edgar Link	pending
0001144204-15-018682-xbrl.zip	Edgar Link	pending
bcli-20141231.xml	Edgar Link	completed
bcli-20141231.xsd	Edgar Link	pending
bcli-20141231_cal.xml	Edgar Link	unprocessable
bcli-20141231_def.xml	Edgar Link	unprocessable
bcli-20141231_lab.xml	Edgar Link	unprocessable
bcli-20141231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ft0001img-1.jpg	Edgar Link	pending
ft0001img-2.jpg	Edgar Link	pending
image_001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v403621_10k.htm	Edgar Link	pending
v403621_ex21.htm	Edgar Link	pending
v403621_ex23-1.htm	Edgar Link	pending
v403621_ex23-2.htm	Edgar Link	pending
v403621_ex31-1.htm	Edgar Link	pending
v403621_ex31-2.htm	Edgar Link	pending
v403621_ex32-1.htm	Edgar Link	pending
v403621_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

2015 Q1 Form 10-K Financial Statement

#000114420415018682 Filed on March 26, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

2015 Q1 Form 10-K Financial Statement

#000114420415018682 Filed on March 26, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli